Stockscreener 앱 받기
114.40
2.44%
2.72
시간 외 거래:
114.00
-0.40
-0.35%
전일 마감가:
$111.68
열려 있는:
$113
하루 거래량:
917.48K
Relative Volume:
1.16
시가총액:
$7.85B
수익:
$217.17M
순이익/손실:
$-202.68M
주가수익비율:
-49.68
EPS:
-2.3028
순현금흐름:
$-156.63M
1주 성능:
+3.04%
1개월 성능:
+32.41%
6개월 성능:
+12.61%
1년 성능:
+72.32%
1일 변동 폭
$110.83
$115.36
1주일 범위
$109.78
$115.36
52주 변동 폭
$64.65
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
114.40 | 7.66B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | RBC Capital Mkts | Outperform |
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
RYTM Maintained by RBC Capital -- Price Target Raised to $141.00 - GuruFocus
RBC Capital Adjusts Rhythm Pharmaceuticals Price Target to $141 From $137, Maintains Outperform Rating - marketscreener.com
Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM - Moomoo
Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
RYTMRhythm Pharmaceuticals Inc Options - Finviz
Rhythm Pharmaceuticals announces public offering of common stock - MSN
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript - GuruFocus
Rhythm Pharmaceuticals (RYTM) CSO exercises RSUs, 2,150 shares withheld for taxes - Stock Titan
Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak - Trefis
Rhythm Pharmaceuticals stock trades up to $111.03 as Rhythm Pharmaceuticals closes offices for July 4th break - Traders Union
Rhythm Pharmaceuticals Stock Surges 28%, With A 12-Day Winning Spree - Trefis
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results? - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with Promising Upside and Strong Buy Ratings - DirectorsTalk Interviews
(RYTM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Rhythm Pharmaceuticals highlights obesity pipeline, shares track sector peers - Ad-hoc-news.de
Rhythm Pharmaceuticals Stock On Fire: Up 26% With 10-Day Winning Streak - Trefis
Rhythm Pharmaceuticals 8-K Filing June 2026 – Company Details, Nasdaq Listing, and Executive Information - Minichart
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director JEAN CHRISTOPHE - Moomoo
Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs - Stock Titan
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MCGIRR DAVID W J - Moomoo
Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units - Stock Titan
Rhythm Pharmaceuticals (RYTM) director granted RSUs, stock options and converts RSUs to shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Arbuckle Stuart A - Moomoo
Rhythm Pharmaceuticals (RYTM) director granted RSUs, options and new shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GOOD JENNIFER L - Moomoo
Rhythm Pharmaceuticals (NASDAQ: RYTM) holders approve directors, pay and Ernst & Young - Stock Titan
Rhythm Pharmaceuticals | 8-K: Current report - Moomoo
Rhythm Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:RYTM) - TradingView
RYTM Forecast — Price Target — Prediction for 2027 - TradingView
Rhythm Pharmaceuticals (RYTM) Is Up 7.9% After Promising Early PWS Data for SetmelanotideWhat's Changed - Sahm
Rhythm Pharmaceuticals(RYTM.US) Director Sells US$3.71 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) director exercises options and sells 37,000 shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director TETRAULT LYNN A. - Moomoo
8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24% - Trefis
Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative - Sahm
Form 144 RHYTHM PHARMACEUTICALS For: 22 June By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals stock surges 4.98% as RhythmPharma announces Dr. Shoemaker joins as Senior Medical Director - Traders Union
Form 144 | Rhythm Pharmaceuticals(RYTM.US) Director Proposes to Sell 3.58 Million in Common Stocks - Moomoo
Rhythm Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
[144] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder? - Insider Monkey
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $105 to $155 - Moomoo
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Rhythm Pharmaceuticals Inc (RYTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals Inc (RYTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rhythm Pharmaceuticals Inc - TradingKey
Rhythm Pharmaceuticals stock price target reiterated at $130 by TD Cowen By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rhythm Pharmaceuticals Inc 주식 (RYTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| TETRAULT LYNN A. | Director |
Jun 22 '26 |
Sale |
100.32 |
37,000 |
3,711,896 |
7,000 |
1.18%
2.48%
자본화:
|
볼륨(24시간):